Agios Pharmaceuticals AGIO Non-Cash Lease Expense
Non-Cash Lease Expense at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's non-cash lease expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's non-cash lease expense?
- Agios Pharmaceuticals (AGIO) reported non-cash lease expense of $3.26M in Q1 2026.
- How has Agios Pharmaceuticals's non-cash lease expense changed year-over-year?
- Agios Pharmaceuticals's non-cash lease expense increased by 8.0% year-over-year, from $3.02M to $3.26M.
- What is the long-term trend for Agios Pharmaceuticals's non-cash lease expense?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's non-cash lease expense has grown at a 6.8% compound annual growth rate (CAGR), from $9.54M to $12.43M.
- What does non-cash lease expense mean?
- Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.